Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CKPTNASDAQ:FULCNASDAQ:VIGLNYSEAMERICAN:XTNT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCKPTCheckpoint Therapeutics$4.26$4.13$1.80▼$4.50$370.71M1.181.43 million shsN/AFULCFulcrum Therapeutics$6.79+0.2%$5.14$2.32▼$10.13$366.03M2.41960,948 shs122,157 shsVIGLVigil Neuroscience$7.87-0.1%$3.90$1.31▼$7.95$367.08M3.43715,462 shs3.04 million shsXTNTXtant Medical$0.65$0.56$0.33▼$0.83$90.36M0.35120,505 shs13,468 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCKPTCheckpoint Therapeutics0.00%0.00%+2.65%+7.30%+110.89%FULCFulcrum Therapeutics-0.73%-4.64%+17.10%+117.31%-12.06%VIGLVigil Neuroscience+0.13%-0.13%+212.30%+289.60%+68.88%XTNTXtant Medical-3.36%-8.10%+8.95%+35.42%-9.46%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCKPTCheckpoint Therapeutics2.556 of 5 stars1.24.00.04.22.70.80.0FULCFulcrum Therapeutics0.4333 of 5 stars1.30.00.00.02.82.50.0VIGLVigil Neuroscience4.0997 of 5 stars4.05.00.00.04.12.50.6XTNTXtant Medical2.9416 of 5 stars3.55.00.00.02.71.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCKPTCheckpoint Therapeutics 2.33Hold$4.331.72% UpsideFULCFulcrum Therapeutics 2.50Moderate Buy$6.29-5.34% DownsideVIGLVigil Neuroscience 2.00Hold$10.8037.49% UpsideXTNTXtant Medical 3.00Buy$1.50129.01% UpsideCurrent Analyst Ratings BreakdownLatest XTNT, FULC, CKPT, and VIGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025FULCFulcrum TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$6.00 ➝ $9.005/28/2025VIGLVigil NeuroscienceStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$11.00 ➝ $8.005/27/2025VIGLVigil NeuroscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$14.00 ➝ $8.005/23/2025FULCFulcrum TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/23/2025FULCFulcrum TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$4.00 ➝ $12.005/23/2025VIGLVigil NeuroscienceMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/22/2025VIGLVigil NeuroscienceJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeHold5/22/2025VIGLVigil NeuroscienceGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Neutral$8.005/22/2025VIGLVigil NeuroscienceCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform5/22/2025VIGLVigil NeuroscienceGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/22/2025VIGLVigil NeuroscienceCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCKPTCheckpoint Therapeutics$41K9,041.59N/AN/A($0.47) per share-9.06FULCFulcrum Therapeutics$80M4.48N/AN/A$3.80 per share1.75VIGLVigil NeuroscienceN/AN/AN/AN/A$3.24 per shareN/AXTNTXtant Medical$91.30M1.00$0.03 per share20.06$0.39 per share1.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCKPTCheckpoint Therapeutics-$51.85M-$1.29N/A∞N/AN/AN/A-659.07%8/11/2025 (Estimated)FULCFulcrum Therapeutics-$97.33M-$0.07N/AN/AN/AN/A-7.31%-6.74%7/30/2025 (Estimated)VIGLVigil Neuroscience-$82.64M-$2.05N/AN/AN/AN/A-83.89%-65.34%8/12/2025 (Estimated)XTNTXtant Medical$660K-$0.13N/A∞N/A-15.45%-37.07%-18.47%8/6/2025 (Estimated)Latest XTNT, FULC, CKPT, and VIGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025CKPTCheckpoint Therapeutics-$0.10-$0.19-$0.09-$0.19$4.53 millionN/A5/7/2025Q1 2025VIGLVigil Neuroscience-$0.53-$0.49+$0.04-$0.49N/AN/A5/1/2025Q1 2025FULCFulcrum Therapeutics-$0.29-$0.28+$0.01-$0.28N/AN/A3/28/2025Q4 2024CKPTCheckpoint Therapeutics-$0.22-$0.69-$0.47-$0.69N/A$0.04 million3/13/2025Q4 2024VIGLVigil Neuroscience-$0.49-$0.57-$0.08-$0.57N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCKPTCheckpoint TherapeuticsN/AN/AN/AN/AN/AFULCFulcrum TherapeuticsN/AN/AN/AN/AN/AVIGLVigil NeuroscienceN/AN/AN/AN/AN/AXTNTXtant MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCKPTCheckpoint TherapeuticsN/A0.290.29FULCFulcrum TherapeuticsN/A18.4418.44VIGLVigil NeuroscienceN/A3.723.72XTNTXtant Medical0.422.120.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCKPTCheckpoint Therapeutics22.00%FULCFulcrum Therapeutics89.83%VIGLVigil Neuroscience83.64%XTNTXtant Medical69.33%Insider OwnershipCompanyInsider OwnershipCKPTCheckpoint Therapeutics2.10%FULCFulcrum Therapeutics7.00%VIGLVigil Neuroscience18.01%XTNTXtant Medical9.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCKPTCheckpoint Therapeutics1087.02 million47.81 millionOptionableFULCFulcrum Therapeutics10053.98 million51.73 millionOptionableVIGLVigil Neuroscience4046.67 million27.38 millionNot OptionableXTNTXtant Medical120139.01 million125.52 millionNot OptionableXTNT, FULC, CKPT, and VIGL HeadlinesRecent News About These CompaniesXtant Medical (NYSEAMERICAN:XTNT) Stock Price Crosses Above 200-Day Moving Average - Should You Sell?June 7, 2025 | marketbeat.comXtant Medical Holdings Inc Share Price (XTNT.US)June 4, 2025 | lse.co.ukXtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Sees Large Drop in Short InterestJune 2, 2025 | marketbeat.comXtant Medical (NYSEAMERICAN:XTNT) Share Price Crosses Above 200 Day Moving Average - Here's WhyMay 31, 2025 | marketbeat.comXtant Medical Announces the Launch of OsteoFactor Pro™May 28, 2025 | prnewswire.comXtant Medical (NYSEAMERICAN:XTNT) Stock Price Crosses Above 200 Day Moving Average - Time to Sell?May 24, 2025 | marketbeat.comXtant Medical (NYSEAMERICAN:XTNT) Share Price Crosses Above Two Hundred Day Moving Average - Should You Sell?May 16, 2025 | marketbeat.comXtant Medical Holdings, Inc. (AMEX:XTNT) Q1 2025 Earnings Call TranscriptMay 13, 2025 | msn.comXtant Medical Holdings, Inc.: Xtant Medical Reports First Quarter 2025 Financial ResultsMay 13, 2025 | finanznachrichten.deXtant Medical Holdings Inc (XTNT) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic ...May 13, 2025 | finance.yahoo.comXtant Medical outlines 8–11% revenue growth target for 2025 as company completes vertical integration and launches new productsMay 13, 2025 | msn.comXtant Medical Holdings, Inc. (XTNT) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comXtant Medical Reports First Quarter 2025 Financial ResultsMay 12, 2025 | prnewswire.com6XTNT : A Glimpse of Xtant Medical Hldgs&#...May 9, 2025 | benzinga.comXtant Medical to Issue First Quarter 2025 Financial Results on May 12, 2025May 6, 2025 | prnewswire.comWhy Xtant Medical Holdings, Inc.’s (XTNT) Stock Is Up 6.27%April 29, 2025 | aaii.comXtant Medical Launches Trivium™ Advanced Bone Graft for Superior PerformanceApril 23, 2025 | prnewswire.comXtant Medical secures investor support, projects Q1 revenue growthApril 18, 2025 | uk.investing.comXtant Medical sees Q1 revenue $32.8M-$33.1M, two estimates $30.65MApril 17, 2025 | markets.businessinsider.comXtant Medical Announces Secondary Private Sale of Existing Shares by OrbiMed and Preliminary First Quarter 2025 Revenue Growth of 18% to 19%April 16, 2025 | prnewswire.comWhy Xtant Medical Holdings, Inc.’s (XTNT) Stock Is Down 14.76%April 10, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeXTNT, FULC, CKPT, and VIGL Company DescriptionsCheckpoint Therapeutics NASDAQ:CKPT$4.26 0.00 (0.00%) As of 05/30/2025Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.Fulcrum Therapeutics NASDAQ:FULC$6.79 +0.01 (+0.18%) As of 02:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Vigil Neuroscience NASDAQ:VIGL$7.86 -0.01 (-0.06%) As of 02:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.Xtant Medical NYSEAMERICAN:XTNT$0.65 0.00 (0.00%) As of 02:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers Certex spinal fixation, Spider cervical plating, Streamline OCT, CervAlign, Axle interspinous fusion, Xpress minimally invasive pedicle screw, Fortex pedicle screw, Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation systems, and Silex sacroiliac joint fusion systems. Further, it provides Calix for cervical and thoracolumbar applications, as well as Irix-C Cervical Integrated Fusion, Irix-A Lumbar Integrated Fusion, Fortilink, and Irix-A Lumbar integrated fusion systems; Coflex device for lumbar spinal stenosis; and CoFix implant for back and disc pain. The company is headquartered in Belgrade, Montana. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: Two Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
